Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

6.41-0.0900-1.38%Vol 7.64K1Y Perf -25.88%
Aug 11th, 2022 15:11 DELAYED
BID5.89 ASK7.22
Open6.88 Previous Close6.50
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.65
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     75.00
Price Range Ratio 52W %
22.22 
Earnings Rating
Market Cap2.15M 
Earnings Date
-
Alpha0.02 Standard Deviation0.12
Beta-0.30 

Today's Price Range

6.056.88

52W Range

5.1710.75

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-
1 Month
-17.40%
3 Months
-1.08%
6 Months
2.56%
1 Year
-25.88%
3 Years
31.35%
5 Years
3.39%
10 Years
183.34%

TickerPriceChg.Chg.%
CYCCP6.41-0.0900-1.38
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-6 235.30
-6 220.70
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
DividendsValueIndustryS&P 500US Markets
8.57
0.60
-2.78
-1.25
Payout ratio-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume7.64K
Shares Outstanding335
Shares Float333.67K
Trades Count60
Dollar Volume48.05K
Avg. Volume231
Avg. Weekly Volume156
Avg. Monthly Volume218
Avg. Quarterly Volume319

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (NASDAQ: CYCCP) stock closed at 6.41 per share at the end of the most recent trading day (a -1.38% change compared to the prior day closing price) with a volume of 7.64K shares and market capitalization of 2.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is -25.88%, while year-to-date (YTD) performance is 3.39%. CYCCP stock has a five-year performance of 3.39%. Its 52-week range is between 5.17 and 10.75, which gives CYCCP stock a 52-week price range ratio of 22.22%

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 13.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.53%, a ROC of -47.85% and a ROE of -50.06%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a dividend yield of 8.57% with a dividend per share of $0.60 and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a Sell technical analysis rating based on Technical Indicators (ADX : 12.67, ATR14 : 0.32, CCI20 : -38.71, Chaikin Money Flow : -1.00, MACD : 0.09, Money Flow Index : 59.49, ROC : 0.31, RSI : 47.75, STOCH (14,3) : 24.10, STOCH RSI : 0.18, UO : 48.03, Williams %R : -75.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

43%57%

Bearish Bullish

54%46%


News

Stocktwits